A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies

Summary

This study is an open-label, single-arm, dose-escalation and dose-expansion study to evaluate the safety, maximum tolerated dose, pharmacokinetic profile in the body after infusion of RS001 injection, and preliminary efficacy in subjects with CD19-positive relapsed/refractory B-cell malignancies (BCM).

Timeline

Start

2025-04-01

Primary completion

2026-04-01

Completion

2028-04-01

Drugs

Indications